Women's College Research Institute, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
JAMA Netw Open. 2018 Aug 3;1(4):e181100. doi: 10.1001/jamanetworkopen.2018.1100.
Patients with ductal carcinoma in situ (DCIS) are treated with radiotherapy to reduce their risk of local invasive recurrence after breast-conserving surgery. However, the association of radiotherapy with breast cancer survival in patients with DCIS has not yet been clearly established.
To determine the extent to which radiotherapy is associated with reduced risk of breast cancer mortality in a large cohort of patients treated for DCIS, using a propensity score-based matching approach.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study of women who had first primary DCIS diagnosed between 1998 and 2014 used data from the Surveillance, Epidemiology, and End Results 18 registries database. Information on age and year of diagnosis, ethnicity, income, tumor size, tumor grade, estrogen receptor status, all treatments (surgery and radiation), and outcomes (invasive local recurrence and death from breast cancer) was abstracted for 140 366 women diagnosed with first primary DCIS. Three separate comparisons were performed using 1:1 matching: lumpectomy with radiation vs lumpectomy alone; lumpectomy alone vs mastectomy; and lumpectomy with radiation vs mastectomy.
Use of radiotherapy and/or extent of surgery.
Crude and adjusted 15-year breast cancer-specific mortality.
Of the 140 366 patients with DCIS in the cohort (109 712 [78.2%] white; mean [SD] age, 58.8 [12.3] years), 35 070 (25.0%) were treated with lumpectomy alone, 65 301 (46.5%) were treated with lumpectomy and radiotherapy, and 39 995 (28.5%) were treated with mastectomy. The actuarial 15-year breast cancer mortality rate was 2.33% for patients treated with lumpectomy alone, 1.74% for patients treated with lumpectomy and radiation, and 2.26% for patients treated with mastectomy. The adjusted hazard ratios for death were 0.77 (95% CI, 0.67-0.88) for lumpectomy and radiotherapy vs lumpectomy alone (29 465 propensity-matched pairs), 0.91 (95% CI, 0.78-1.05) for mastectomy alone vs lumpectomy alone (20 832 propensity-matched pairs), and 0.75 (95% CI, 0.65-0.87) for lumpectomy and radiotherapy vs mastectomy (29 865 propensity-matched pairs).
In patients with DCIS, treatment with lumpectomy and radiotherapy was associated with a significant reduction in breast cancer mortality compared with either lumpectomy alone or mastectomy alone. This suggests that the survival benefit of radiation is likely not due to local control, but rather to systemic effects.
保乳手术后,采用放射疗法可降低导管癌原位(DCIS)患者的局部侵袭性复发风险。然而,放射疗法与 DCIS 患者的乳腺癌生存之间的关联尚未明确。
使用倾向评分匹配方法,在接受 DCIS 治疗的大量患者队列中,确定放射疗法在多大程度上降低了乳腺癌死亡率。
设计、地点和参与者:这项对 1998 年至 2014 年间首次诊断为原发性 DCIS 的女性进行的队列研究使用了监测、流行病学和最终结果 18 个登记处数据库的数据。从数据库中提取了 140366 名女性的年龄和诊断年份、种族、收入、肿瘤大小、肿瘤分级、雌激素受体状态、所有治疗方法(手术和放疗)和结局(局部侵袭性复发和乳腺癌死亡)信息。针对以下三种情况分别进行了 1:1 匹配:保乳术加放疗与单纯保乳术;单纯保乳术与乳房切除术;保乳术加放疗与乳房切除术。
放疗和/或手术范围的使用。
未经调整和调整后的 15 年乳腺癌特异性死亡率。
在队列中 140366 名患有 DCIS 的患者中(109712 名[78.2%]为白人;平均[标准差]年龄为 58.8[12.3]岁),35070 名(25.0%)接受单纯保乳术治疗,65301 名(46.5%)接受保乳术加放疗,39995 名(28.5%)接受乳房切除术治疗。单纯保乳术、保乳术加放疗和乳房切除术治疗患者的 15 年乳腺癌死亡率分别为 2.33%、1.74%和 2.26%。保乳术加放疗与单纯保乳术相比,死亡风险的调整后比值比为 0.77(95%CI,0.67-0.88)(29465 对倾向评分匹配的对),乳房切除术与单纯保乳术相比,调整后比值比为 0.91(95%CI,0.78-1.05)(20832 对倾向评分匹配的对),保乳术加放疗与乳房切除术相比,调整后比值比为 0.75(95%CI,0.65-0.87)(29865 对倾向评分匹配的对)。
在患有 DCIS 的患者中,与单纯保乳术或乳房切除术相比,保乳术加放疗治疗与显著降低乳腺癌死亡率相关。这表明放射治疗的生存获益可能不是由于局部控制,而是由于全身效应。